Literature DB >> 2653793

Current management of polymyositis and dermatomyositis.

C V Oddis1, T A Medsger.   

Abstract

This article reviews the clinical features and emphasises the treatment of polymyositis and dermatomyositis. Pharmacological intervention with corticosteroids and immunosuppressive agents is discussed. In addition, strategies regarding the initiation and subsequent tapering of these drugs are provided, and an algorithmic approach to the management of myositis is provided. Therapeutic modalities for patients with refractory disease are considered, and the potential adverse effects of such treatment are discussed. Since patients with myositis often have disease-related complaints other than muscle weakness, a practical treatment approach for these problems is also outlined.

Entities:  

Mesh:

Year:  1989        PMID: 2653793     DOI: 10.2165/00003495-198937030-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  23 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.

Authors:  A Bohan; J B Peter; R L Bowman; C M Pearson
Journal:  Medicine (Baltimore)       Date:  1977-07       Impact factor: 1.889

3.  Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy.

Authors:  A L Metzger; A Bohan; L S Goldberg; R Bluestone; C M Pearson
Journal:  Ann Intern Med       Date:  1974-08       Impact factor: 25.391

4.  The epidemiology of polymyositis.

Authors:  T A Medsger; W N Dawson; A T Masi
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

5.  Reversal of chronic polymyositis following intravenous immune serum globulin therapy.

Authors:  C M Roifman; F M Schaffer; S E Wachsmuth; G Murphy; E W Gelfand
Journal:  JAMA       Date:  1987 Jul 24-31       Impact factor: 56.272

6.  Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis.

Authors:  D J Wallace; A L Metzger; K K White
Journal:  Arthritis Rheum       Date:  1985-05

7.  Clinical characteristics and course in patients with high titer anti-RNP antibodies.

Authors:  J P Lemmer; N H Curry; J H Mallory; M V Waller
Journal:  J Rheumatol       Date:  1982 Jul-Aug       Impact factor: 4.666

8.  Dermatomyositis without creatine kinase elevation. A poor prognostic sign.

Authors:  E J Fudman; T J Schnitzer
Journal:  Am J Med       Date:  1986-02       Impact factor: 4.965

9.  Prednisone and azathioprine for polymyositis: long-term followup.

Authors:  T W Bunch
Journal:  Arthritis Rheum       Date:  1981-01

10.  The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis.

Authors:  S Yoshida; M Akizuki; T Mimori; H Yamagata; S Inada; M Homma
Journal:  Arthritis Rheum       Date:  1983-05
View more
  4 in total

Review 1.  Polymyositis/dermatomyositis: the current position.

Authors:  A Urbano-Márquez; J Casademont; J M Grau
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

2.  Idiopathic inflammatory myopathy: treatment options.

Authors:  Stephen J DiMartino
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

Review 3.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

4.  Dermatomyositis onset in the puerperium period.

Authors:  Sofia Mateus; Mariana Malheiro; Miguel Perneta Santos; Rui Costa
Journal:  BMJ Case Rep       Date:  2015-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.